; or (B) after review of such response, the manufacturer had a reasonable basis for not notifying as required under subsection (a). 544. State testing report For any State that authorizes (or intends to authorize) one or more laboratories in the State to develop and perform in vitro diagnostic COVID–19 tests, the head of the department or agency of such State with primary responsibility for health shall— (1) notify the Secretary of such authorization (or intention to authorize); and (2) provide the Secretary with a weekly report— (A) identifying all laboratories authorized (or intended to be authorized) by the State to develop and perform in vitro diagnostic COVID–19 tests; (B) including relevant information on all laboratories identified pursuant to subparagraph (A), which may include information on laboratory testing capacity; (C) identifying all in vitro diagnostic COVID–19 tests developed and approved for clinical use in laboratories identified pursuant to subparagraph (A); and (D) including relevant information on all tests identified pursuant to subparagraph (C), which may include— (i) the name and contact information of the developer of any such test; (ii) any fact sheets, manufacturer instructions, and package inserts for any such test, including information on intended use; and (iii) the sensitivity and specificity of any such test. 545. State listing of testing sites Not later than 14 days after the date of enactment of this Act, any State receiving funding or assistance under this Act, as a condition on such receipt, shall establish and maintain a public, searchable webpage on the official website of the State that— (1) identifies all sites located in the State that provide diagnostic or serological testing for SARS–CoV–2